Clinical trials
Biliary Tract Diseases clinical trials
Below are recruiting biliary tract diseases clinical trials, each written for real people, not researchers. We’re tracking 119 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07569679RecruitingPhase 2
Combination Chemotherapy and Immunotherapy for Biliary Tract Cancer
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
Xi'an, ShaanxiAges 18 years+ - NCT07450976RecruitingPhase 2
Targeted drug for advanced biliary tract cancer after standard treatment
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07267078RecruitingPhase 2
Tuvonralimab and Iparomlimab before surgery for bile duct cancer
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05065957RecruitingPhase 2/Phase 3
Study of two oral chemo medicines for advanced bile duct cancer
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
Kaohsiung CityAges 18 years+ - NCT07156058Recruiting
Personalized therapy after surgery for bile duct cancer
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
BeijingAges 18 years+ - NCT06938321RecruitingPhase 1/Phase 2
New drug combo for advanced bile duct and gallbladder cancer
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06622057RecruitingPhase 3
D07001 and capecitabine for advanced bile duct cancer
This trial tests a combination of two oral medications, D07001 and capecitabine, for people with advanced bile duct, gallbladder, or ampullary cancer that has gotten worse after standard chemotherapy. The goal is to see if this combination can help control the cancer.
Tucson, ArizonaAges 18 years+ - NCT06546969RecruitingPhase 1
Combination therapy for advanced bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
Baltimore, MarylandAges 21 years+ - NCT06467357RecruitingPhase 3
New drug combo for advanced bile duct cancer with HER2
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
Scottsdale, ArizonaAges 18–99 - NCT06431490RecruitingPhase 1/Phase 2
Testing TQB2102 for HER2-positive bile duct cancer
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
Fuyang, AnhuiAges 18–75 - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+ - NCT06230471RecruitingPhase 2
Pembrolizumab plus lenvatinib or chemo for advanced bile duct cancer
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
Beijing, Beijing MunicipalityAges 18–80 - NCT05668884RecruitingPhase 2
Testing three drugs for advanced bile duct cancer
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07790445RecruitingPhase 4
Adjuvant chemotherapy for bile duct cancer after surgery
This study tests whether giving chemotherapy directly into the liver (HAIC) plus an oral chemo pill (capecitabine) after surgery helps prevent bile duct cancer from coming back, compared to just the pill. It's for people who recently had their cancer completely removed.
Zhengzhou, HenanAges 18 years+ - NCT06708858RecruitingPhase 2
Studying surufatinib with chemo and immunotherapy for advanced bile duct cancer
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06749730RecruitingPhase 2
Study of four drugs for advanced bile duct cancer
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
ZhengzhouAges 18–80 - NCT07392541RecruitingPhase 1/Phase 2
Study of adebrelimab plus chemo and simvastatin for bile duct cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
Wuhan, HubeiAges 18 years+ - NCT07036380RecruitingPhase 2
Testing MP0317 with chemotherapy for advanced bile duct cancer
This trial tests if adding a new drug (MP0317) to standard chemoimmunotherapy helps people with advanced bile duct cancer. It's for patients who haven't had treatment yet, except for certain past adjuvant therapy.
BesançonAges 18 years+ - NCT06978114RecruitingPhase 2
Study of a new drug for advanced bile duct cancer
This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05942807Recruiting
Study of biliary tract cancer and care experiences
This is an observational study for adults with biliary tract cancer that looks at existing clinical information. It may help doctors understand the disease better and improve future care, without using a new treatment in a required way.
Roma, RomeAges 18 years+ - NCT06564623RecruitingPhase 1
Peptide vaccine plus immunotherapy for biliary tract cancer
This trial tests a personalized peptide vaccine combined with two immunotherapy drugs (durvalumab and tremelimumab) for patients with biliary tract cancer whose tumors have specific genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
Baltimore, MarylandAges 18 years+ - NCT06548412RecruitingPhase 1/Phase 2
New drug combo for first-line treatment of advanced bile duct cancer
This trial tests a new drug called CTX-009 combined with three standard chemotherapy drugs (gemcitabine, cisplatin, and durvalumab) as a first treatment for bile duct cancer that cannot be removed by surgery or has spread. It aims to see if this combination is safe and effective.
Houston, TexasAges 18 years+ - NCT06529718RecruitingPhase 2
Ivonescimab vs FOLFOX for advanced bile duct cancer
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
AmiensAges 18 years+ - NCT05640791RecruitingPhase 2
Durvalumab with chemo before surgery for bile duct cancer
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Biliary Tract Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract diseases?
- Yes. Clin2 currently lists 119 recruiting biliary tract diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.